Sales and net income reach all-time highs

6% dividend increase proposed / Positive Group outlook for 2015

(lifePR) ( Bad Homburg, )
Ulf Mark Schneider, CEO of Fresenius, said: "2014 was a challenging but successful year for Fresenius. We made significant progress on the integration of the Rhön hospitals, strengthened the Care Coordination initiatives at Fresenius Medical Care, and set new sales and earnings records for the Group. Fresenius sees significant opportunities arising from the increasing demand for affordable, high-quality health care around the globe. We remain highly optimistic about the growth prospects in all our business segments for 2015 and beyond."

22nd consecutive dividend increase proposed
Based on the strong financial results, the Management Board will propose to the Supervisory Board a dividend increase of 6% to €0.44 per share (2013: €1.25 pre 1:3 share split). The total dividend distribution is expected to be €238 million.

Positive Group outlook for 2015
For 2015, Fresenius projects sales growth of 7% to 10% in constant currency. Net income1 is expected to increase by 9% to 12% in constant currency.

The net debt/EBITDA2 ratio is expected to be at approximately 3.0 at the end of 2015.

16% constant currency sales growth - at top end of guidance
Group sales increased by 14% (16% in constant currency) to €23,231 million (2013: €20,331 million). Organic sales growth was 4%. Currency translation had a negative effect of 2%. Acquisitions contributed 12%. Divestitures had a marginal effect on sales growth.

In Q4/2014, Group sales increased by 23% (20% in constant currency) to €6,520 Million (Q4/2013: €5,299 million). Organic sales growth was 6%.

1 Net income attributable to shareholders of Fresenius SE & Co. KGaA; 2015 before integration costs (~€10 million before tax for hospitals acquired from Rhön-Klinikum AG), before costs for the efficiency program at Fresenius Kabi (~€100 million before tax), and before the gain from the divestment of two HELIOS hospitals (€34 million before tax); 2014 before special items
2 At annual average exchange rates for both net debt and EBITDA; without major acquisitions; before special items
Für die oben stehenden Pressemitteilungen, das angezeigte Event bzw. das Stellenangebot sowie für das angezeigte Bild- und Tonmaterial ist allein der jeweils angegebene Herausgeber (siehe Firmeninfo bei Klick auf Bild/Meldungstitel oder Firmeninfo rechte Spalte) verantwortlich. Dieser ist in der Regel auch Urheber der Pressetexte sowie der angehängten Bild-, Ton- und Informationsmaterialien.
Die Nutzung von hier veröffentlichten Informationen zur Eigeninformation und redaktionellen Weiterverarbeitung ist in der Regel kostenfrei. Bitte klären Sie vor einer Weiterverwendung urheberrechtliche Fragen mit dem angegebenen Herausgeber. Bei Veröffentlichung senden Sie bitte ein Belegexemplar an service@lifepr.de.